Shanghai GMS Pharmaceutical

GMS Pharmaceutical (Shanghai) is a leading radiopharmaceutical company in China, operating as a key subsidiary of Global Medical Solutions (GMS). The company specializes in the development, manufacturing, and distribution of diagnostic and therapeutic radiopharmaceuticals used in nuclear medicine, including PET and SPECT imaging agents. With an extensive network of radiopharmacies across mainland China, GMS provides critical products such as 18F-FDG and Technetium-99m generators to hospitals and clinics. The company also offers centralized radiopharmacy services and equipment maintenance for nuclear medicine departments. In 2024, Haier Group acquired a 90% stake in the parent company, GMS, for approximately $585 million to strengthen its position in the high-growth radiopharmaceutical sector.